ESSURE ESS305

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a consumer,other report with the FDA on 2020-03-26 for ESSURE ESS305 manufactured by Bayer Pharma Ag.

Event Text Entries

[185906367] This spontaneous case was reported by a lawyer and describes the occurrence of pelvic pain ('pelvic pain'), vaginal haemorrhage ('abnormal bleeding (vaginal)'), menorrhagia ('abnormal bleeding (menorrhagia)'), endometrial disorder ('endometrium') and ovarian cystectomy ('right ovarian cyst removal') in an adult female patient who had essure (batch no. 627739) inserted for female sterilisation. The occurrence of additional non-serious events is detailed below. The patient's medical history included ovarian cyst, chest discomfort, muscle ache, diarrhea, adhd, dysfunctional uterine bleeding, uterine bleeding and metrorrhagia. On (b)(6) 2008, the patient had essure inserted. On an unknown date, the patient experienced pelvic pain (seriousness criteria medically significant and intervention required), vaginal haemorrhage (seriousness criteria medically significant and intervention required), menorrhagia (seriousness criteria medically significant and intervention required), endometrial disorder (seriousness criterion medically significant), depression ("depression"), anxiety ("anxiety"), skin lesion ("skin lesions"), mitral valve prolapse ("mitral valve prolapse"), anaemia ("anemia"), nausea ("nausea"), dysmenorrhoea ("dysmenorrhea (cramping)"), dyspareunia ("dyspareunia (painful sexual intercourse)"), vaginal discharge ("vaginal discharge"), irritable bowel syndrome ("irritable bowel syndrome"), diverticulum ("diverticulosis"), constipation ("constipation") and abdominal pain ("right and left abdomen pain"), underwent ovarian cystectomy (seriousness criterion medically significant) and was found to have weight increased ("weight gain"). The patient was treated with surgery (d&c, on (b)(6) 2018 underwent ablation, d&c and unilateral oopherectomy, bilateral salpingectomy). Essure was removed on (b)(6) 2018. At the time of the report, the pelvic pain, menorrhagia, endometrial disorder, ovarian cystectomy, depression, anxiety, skin lesion, mitral valve prolapse, anaemia, nausea, dyspareunia, vaginal discharge, weight increased, irritable bowel syndrome, diverticulum, constipation and abdominal pain outcome was unknown and the vaginal haemorrhage and dysmenorrhoea had resolved. The reporter considered abdominal pain, anaemia, anxiety, constipation, depression, diverticulum, dysmenorrhoea, dyspareunia, endometrial disorder, irritable bowel syndrome, menorrhagia, mitral valve prolapse, nausea, ovarian cystectomy, pelvic pain, skin lesion, vaginal discharge, vaginal haemorrhage and weight increased to be related to essure. The reporter commented: previously reported essure insertion date : 2007. The right one with coils seen, the left one with two coils seen. Diagnostic results (normal ranges are provided in parenthesis if available): hysterosalpingogram - on an unknown date: total bilateral occlusion. Most recent follow-up information incorporated above includes: on (b)(6) 2020: pfs and mr received : previously reported event "injury" updated to "abnormal bleeding (vaginal)", events- "abnormal bleeding (menorrhagia), depression, anxiety, skin lesions, mitral valve prolapse, anemia, nausea, dysmenorrhea (cramping), right ovarian cyst removal, dyspareunia (painful sexual intercourse), vaginal discharge, weight gain, irritable bowel syndrome, diverticulosis, constipation, endometrium, pelvic pain, right and left abdomen pain", reporter, lot number, medical history, lab data added. We received a lot number in this case. A technical investigation will be conducted, including a batch review, and a review of complaint records and other relevant data; should any new and reportable information become available from our investigation, this will be provided in a supplementary report.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number2951250-2020-02739
MDR Report Key9881975
Report SourceCONSUMER,OTHER
Date Received2020-03-26
Date of Report2020-03-27
Date Mfgr Received2020-03-03
Date Added to Maude2020-03-26
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactK SHAW LAMBERSON
Manufacturer Street100 BAYER BLVD, P.O. BOX 915
Manufacturer CityWHIPPANY NJ 07981
Manufacturer CountryUS
Manufacturer Postal07981
Manufacturer G1BAYER PHARMA AG
Manufacturer StreetM
Manufacturer CityBERLIN, 13353
Manufacturer CountryGM
Manufacturer Postal Code13353
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameESSURE
Generic NameTRANSCERVICAL CONTRACEPTIVE TUBAL OCCLUSION DEVICE
Product CodeHHS
Date Received2020-03-26
Model NumberESS305
Lot Number627739
OperatorHEALTH PROFESSIONAL
Device Availability*
Device AgeDA
Device Eval'ed by MfgrN
Device Sequence No1
Device Event Key0
ManufacturerBAYER PHARMA AG
Manufacturer AddressM?LLERSTR. 178 BERLIN, 13353 GM 13353


Patients

Patient NumberTreatmentOutcomeDate
101. Other; 2. Required No Informationntervention 2020-03-26

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.